Want to see IN:HCG full AI Analyst Report?
HCG Stock Chart & Stats
₹666.25
₹10.40(1.56%)
At close: 4:00 PM EDT
₹666.25
₹10.40(1.56%)
Day’s Range― - ―
52-Week Range₹513.40 - ₹799.36
Previous CloseN/A
Volume148.81K
Average Volume (3M)106.82K
Market Cap
₹105.80B
Enterprise Value₹88.39K
Total Cash (Recent Filing)₹5.41B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)454.0
Beta0.48
Next Earnings
Nov 05, 2026EPS Estimate
1.97Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.56
Shares Outstanding149,302,200
10 Day Avg. Volume182,354
30 Day Avg. Volume106,820
Financial Highlights & Ratios
PEG Ratio-7.78
Price to Book (P/B)5.59
Price to Sales (P/S)2.93
P/FCF Ratio135.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)9
Revenue Forecast (FY)₹29.06B
Bulls Say, Bears Say
Bulls Say
Revenue Scale And ExpansionThe substantial five-year revenue increase indicates expanding patient activity and a larger operating base. HCG’s integrated oncology network spans screening, diagnostics, treatment and follow-up care, supporting durable demand across the cancer-care continuum.
Operating Cash GenerationSustained growth in operating cash flow provides internal funding for debt service, hospital investment and ongoing operations. This cash-generation capability is an important counterbalance to thin earnings and supports financial resilience over the medium term.
Improved Equity BaseThe sizeable increase in equity strengthens the capital base and improves balance-sheet resilience despite elevated debt. A larger equity cushion can support continued investment in oncology capacity while reducing some sensitivity to operating volatility.
Bears Say
High And Rising LeverageDebt materially exceeds equity and has increased substantially over recent years. This debt-heavy structure can raise interest and refinancing exposure, constrain capital allocation and make earnings more sensitive to changes in hospital utilization or operating costs.
Thin And Deteriorating ProfitabilityVery low net profitability leaves limited protection against cost inflation, depreciation or financing burdens. The recent margin compression also reduces the company’s ability to convert revenue growth into retained earnings and internally funded expansion.
Slower Revenue GrowthThe sharp deceleration in revenue growth suggests that the benefits of prior expansion are moderating. Slower top-line momentum may make it harder to absorb fixed hospital costs, deleverage quickly and restore profitability without stronger productivity or capacity utilization.
HealthCare Global Enterprises Ltd. News
HCG FAQ
What was HealthCare Global Enterprises Ltd.’s price range in the past 12 months?
HealthCare Global Enterprises Ltd. lowest stock price was ₹513.40 and its highest was ₹799.36 in the past 12 months.
What is HealthCare Global Enterprises Ltd.’s market cap?
HealthCare Global Enterprises Ltd.’s market cap is ₹105.80B.
When is HealthCare Global Enterprises Ltd.’s upcoming earnings report date?
HealthCare Global Enterprises Ltd.’s upcoming earnings report date is Nov 05, 2026 which is in 44 days.
How were HealthCare Global Enterprises Ltd.’s earnings last quarter?
HealthCare Global Enterprises Ltd. released its earnings results on Aug 06, 2026. The company reported ₹0.95 earnings per share for the quarter, missing the consensus estimate of ₹2.79 by -₹1.84.
Is HealthCare Global Enterprises Ltd. overvalued?
According to Wall Street analysts HealthCare Global Enterprises Ltd.’s price is currently Overvalued.
Does HealthCare Global Enterprises Ltd. pay dividends?
HealthCare Global Enterprises Ltd. does not currently pay dividends.
What is HealthCare Global Enterprises Ltd.’s EPS estimate?
HealthCare Global Enterprises Ltd.’s EPS estimate is 1.97.
How many shares outstanding does HealthCare Global Enterprises Ltd. have?
HealthCare Global Enterprises Ltd. has 149,302,200 shares outstanding.
What happened to HealthCare Global Enterprises Ltd.’s price movement after its last earnings report?
HealthCare Global Enterprises Ltd. reported an EPS of ₹0.95 in its last earnings report, missing expectations of ₹2.79. Following the earnings report the stock price went up 0.172%.
Which hedge fund is a major shareholder of HealthCare Global Enterprises Ltd.?
Currently, no hedge funds are holding shares in IN:HCG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
HealthCare Global Enterprises Ltd.
HealthCare Global Enterprises Limited, founded in 1989 and headquartered in Bengaluru, India, delivers comprehensive healthcare services with a primary focus on oncology. The company offers a full spectrum of cancer care, from diagnosis to various treatment modalities such as radiation therapy, medical oncology, and surgical procedures. Beyond its core cancer services, HCG also operates in the field of fertility and reproductive medicine under its Milann brand. This includes services like assisted reproduction, gynecological endoscopy, and fertility preservation. The enterprise further manages four multi-specialty hospitals: three branded HCG facilities located in Ahmedabad, Bhavnagar, and Rajkot in Gujarat, and one in Hubli, Karnataka, operated under a management contract. These hospitals cater to diverse medical specialities including cardiology, neurology, orthopedics, gastroenterology, urology, internal medicine, pulmonary care, and critical care. Additionally, HealthCare Global provides medical diagnostic services, offering scientific testing and consultancy for the pharmaceutical and broader medical industries. As of March 31, 2021, its extensive network comprised 23 cancer centers throughout India, featuring a center of excellence in Bengaluru, alongside two independent diagnostic centers and one day-care chemotherapy unit. The company also maintains an international presence with a cancer center established in Africa.
Technical Analysis
Apollo Hospitals Enterprise Limited
―
Aster DM Healthcare Ltd.
―
Fortis Healthcare Ltd.
―
Max Healthcare Institute Ltd
―
Global Health Limited
―